News
“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.
Merck is closing in on a $10bn (€8.5bn) deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results